A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03797391 |
Recruitment Status :
Recruiting
First Posted : January 9, 2019
Last Update Posted : May 31, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Neoplasms Neoplasm Metastasis Non-Small-Cell Lung Cancer | Drug: EMB-01 | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 186 participants |
Allocation: | N/A |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | Dose escalation followed by Protocol at 100mg, 200mg, 350mg, 500mg, 700mg, 900mg, 1200mg, 1600mg, 2100mg, 2700mg and 3000mg . |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients With Advanced/Metastatic Solid Tumors |
Actual Study Start Date : | December 13, 2018 |
Estimated Primary Completion Date : | March 14, 2025 |
Estimated Study Completion Date : | January 15, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Dose Escalation-Part 1, Expansion-Part 2
In part 1, escalating dose cohort, patients will receive intravenous infusions of EMB-01 weekly (QW). The duration of each treatment cycle is 28 days (4 weeks). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered. In part 2, participants will receive intravenous infusion of EMB-01 at the recommended Phase II dose (RP2D) regimen(s) once weekly. The duration of each treatment cycle is 28 days (4 weeks). |
Drug: EMB-01
In part 1, patients will receive intravenous infusions of EMB01 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase II dose (RP2D) is reached or all planned doses are administered. In part 2, participants will receive intravenous infusion of EMB-01 at RP2D The duration of each treatment cycle in both part 1 and part 2 is 28 days (4 weeks). Participants may continue to receive study drug until discontinuation criteria are met. Other Name: FIT-013a |
- Maximum tolerated dose (MTD) (phase 1 only) [ Time Frame: cycle 1 (1cycle = 28 days) ]Maximum tolerated dose
- Adverse Events (AEs), and Serious Adverse Events (SAEs) [ Time Frame: Screening up to follow-up (30 days after the last dose) ]Adverse Events, and Serious Adverse Events
- Overall Response Rate (ORR) (phase 2 only) [ Time Frame: From the date fo dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months ]Overall Response Rate
- Maximum Serum Concentration (Cmax) [ Time Frame: Through treatment discontinuation: an average of 6 months ]Maximum Serum Concentration
- Area Under the Plasma Concentration-Time Curve (AUC) [ Time Frame: Through treatment discontinuation: an average of 6 months ]Area Under the Plasma Concentration-Time Curve
- Trough Serum Concentration (Ctrough) [ Time Frame: Through treatment discontinuation: an average of 6 months ]Trough Serum Concentration
- Elimination half-life (t1/2) [ Time Frame: Through treatment discontinuation: an average of 6 months ]Elimination half-life
- Clearance (CL) [ Time Frame: Through treatment discontinuation: an average of 6 months ]Clearance
- Volume of distribution at steady state (Vss) [ Time Frame: Through treatment discontinuation: an average of 6 months ]volume of distribution at steady state
- Accumulation Ratio (AR) [ Time Frame: hrough treatment discontinuation: an average of 6 months ]Accumulation Ratio
- Dose Proportionality [ Time Frame: Through treatment discontinuation: an average of 6 months ]Dose Proportionality
- Anti-Drug Antibodies (ADA) [ Time Frame: Through study completion, an average of 7 months ]Anti-Drug Antibodies
- Duration Of Response (DOR) [ Time Frame: From the date fo dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months ]Duration Of Response
- Progression-Free Survival (PFS) [ Time Frame: Through treatment discontinuation: an average of 6 months ]Progression-free survival
- Pharmacodynamic (Soluble EGFR and cMET concentration) [ Time Frame: Through treatment discontinuation: an average of 6 months ]Pharmacodynamic (Soluble EGFR and cMET concentration)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Molecular Pre-screening Inclusion criteria (Phase II only)
- The patient must sign the molecular pre-screening Inform Consent to allow for the molecular pre-screening process. All patients must have documented evidence of EGFR and/or cMet aberrations.
Screening Inclusion Criteria
- Able to understand and willing to sign the Informed Consent Form (ICF).
-
Histologically/cytologically confirmed advanced/metastatic solid tumors with measurable disease [Response Evaluation Criteria in Solid Tumors (RECIST) v1.1]:
Phase I: advanced/metastatic solid tumors including but not limited to NSCLC, colorectal cancer, gastric cancer and liver cancer refractory to standard therapy or for which no standard therapy is available or accessible.
Phase II: Advanced/metastatic NSCLC Patients have confirmed EGFR mutant and/or cMET aberration, and have progressed after standard treatment (including platinum-based therapy) or are intolerant to standard treatment. Additionally, patients with T790M mutation have received FDA/Health Authority approved therapies (if accessible) for this indication (i.e., osimertinib) and have progressed or became intolerant.
A patient who has refused all currently available therapy is allowed to enroll, but must be documented in the source record.
- Must have adequate organ function.
-
Regarding prior anti-tumor therapy:
- Must have stopped treatment at least 4 weeks or within 5 half-lives.
- Generalized radiation therapy must have stopped 3 weeks before first dose of EMB 01, or local radiotherapy or radiation therapy for bone metastases must have stopped 2 weeks before first dose of EMB-01. No therapeutic radiopharmaceuticals are taken within 8 weeks before first dose of EMB-01.
- Patients must have recovered to ≤Grade 1 from the adverse effects of such above treatment before beginning study treatment.
- Female patient with fertility or male patient whose partner has fertility should use one or more contraceptive methods for contraception starting from screening period and continue throughout the study treatment and for 3 months.
- ECOG score 0 or 1 for phase I, and ≤2 for phase II.
Exclusion Criteria:
Molecular Pre-screening Exclusion Criteria (Phase II only)
Subject who meets any of the follow criteria can't be proceeded to clinical screening:
- Patients who are unwilling to sign the molecular pre-screening ICF.
- Patients for whom local EGFR and/or cMET data or the results of central laboratory testing do not meet the molecular pre-screening inclusion criteria.
Screening Exclusion Criteria
- Life expectancy < 3 months.
- Subject with primacy central nervous system (CNS) malignancy or symptomatic CNS (leptomeningeal or brain) metastases.
- Pregnant or nursing females.
- Subjects who have had major surgery within 28 days prior to screening.
- Serious underlying medical conditions, including but not limited to un-controlled hypertension, other cardiovascular disease or diabetes, ongoing or active infection, psychiatric, psychological, familial or geographical condition that, in the judgment of the investigator, may interfere the compliance with study treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03797391
Contact: Xiaodong Sun, MD | +86-21-61043299 | xdsun@epimab.com | |
Contact: Xuemei Xie | +86-21-61043299 | xmxie@epimab.com |
United States, Massachusetts | |
Dana-Farber Cancer Institute | Recruiting |
Boston, Massachusetts, United States, 02215 | |
United States, Michigan | |
Barbara Ann Karmanos Cancer Institute | Recruiting |
Detroit, Michigan, United States, 48201 | |
United States, Ohio | |
Gabrail Cancer Center Research | Recruiting |
Canton, Ohio, United States, 44718 | |
China, Guang Dong | |
Guangdong General Hospital | Recruiting |
Guangzhou, Guang Dong, China, 510080 | |
China, Shanghai | |
Shanghai Chest Hosptial | Recruiting |
Shanghai, Shanghai, China, 200030 |
Responsible Party: | Shanghai EpimAb Biotherapeutics Co., Ltd. |
ClinicalTrials.gov Identifier: | NCT03797391 |
Other Study ID Numbers: |
EMB01X101 |
First Posted: | January 9, 2019 Key Record Dates |
Last Update Posted: | May 31, 2023 |
Last Verified: | May 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Human Bispecific antibody, Epidermal Growth Factor Receptor (EGFR), c-Mesenchymal-Epithelial Transition (cMet), |
Neoplasms, Neoplasm Metastasis, Non-Small-Cell Lung Cancer (NSCLC), First-in-human, EMB-01, Tyrosine Kinase Inhibitor (TKI) Resistant |
Neoplasms Carcinoma, Non-Small-Cell Lung Neoplasm Metastasis Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Neoplastic Processes Pathologic Processes |